Skip to main content

Table 1 Participant characteristics and HR-QOL results

From: Health-related quality of life of young adults with Turner syndrome following a long-term randomized controlled trial of recombinant human growth hormone

 

Randomized to growth hormone injections until adult height

Randomized to no injections

Number

21

12

Age (years)

20.0 (SD 2.4)

20.2 (SD 2.1)

Height (cm)

148.9 (SD 5.7)

143.7 (SD 6.1)

BMI (kg/m2)

25.7 (SD 4.9)

24.2 (SD 3.7)

Adherence

20 received injections

10 did not receive growth hormone injections

SF-36 PCS

56 (SD 4.9)

58 (SD 4.2)

SF-36 MCS

52 (SD 6.3)

49 (SD 13.2)

SF-36 subscales with norms

  

Physical Functioning

54 (SD 5.9)

55 (SD 2.7)

Role Physical

56 (SD not calculable)

55 (SD 2.8)

Bodily Pain

58 (SD 5.4)

59 (SD 4.7)

General Health

53 (SD 6.4)

56 (SD 6.9)

Vitality

56 (SD 7.3)

55 (SD 7.8)

Social Functioning

53 (SD 7.5)

51 (SD 9.9)

Role Emotional

54 (SD 5.0)

49 (SD 11)

Mental Health

52 (SD 5.7)

50 (SD 11)